Tag: US FDA

  • Iovance Biotherapeutics (IOVA) Sees Volume Spike on Goldman Note

    Iovance Biotherapeutics (IOVA) Sees Volume Spike on Goldman Note

    Investors may want to keep an eye on Iovance Biotherapeutics (IOVA). According to Goldman Sachs, the biopharma stock could double from its current price of $5.49 a share. In fact, the firm says it could rally to $12, pointing to the potential approval of the company’s treatment by February 2024. “With accelerated approval, lifileucel would…

  • It May be Time to Invest in Psychedelics Again

    It May be Time to Invest in Psychedelics Again

    Psychedelic stocks could be far out, nan. Just today, stocks like Mind Medicine (MNMD) were up about 8% on a volume spike to 2.85 million shares, as compared to daily average volume of 1.3 million. All after Sen. Cory Booker tweeted, “Massive breakthroughs in medical studies with psilocybin and MDMA are showing strong promise for…